期刊文献+

三维适形放射治疗对胰腺癌患者生活质量的影响与预后相关因素分析 被引量:4

Therapeutic evaluation on 3-dimensional conformal radiation therapy by analyz ing the quality of life involved in the analysis of prognostic factors in pancre atic cancer patients
暂未订购
导出
摘要 目的:探讨三维适形放射治疗(3-dimensionalconformalradiationtherapy,3DCRT)技术治疗胰腺癌的疗效及生活质量,分析影响预后的因素。方法:31例胰腺癌患者采用3DCRT技术治疗,观察肿瘤局部控制率及1,2年生存率,采用生活质量评分量表进行日常生活活动、疼痛、食欲、睡眠等13项内容综合评估,并用Cox回归比例风险模型分析预后因素。结果:3,12个月时肿瘤局部控制率分别为58.1%,32.3%,1,2年生存率分别是38.2%,7.6%,中位生存期8.3个月。多因素分析结果显示临床分期、生活质量评分对患者生存率的影响具有统计学意义(P<0.05)。结论:3DCRT治疗胰腺癌,能明显改善患者的生活质量及提高生存率,临床分期和生活质量评分对胰腺癌患者的预后有重要影响。 AIM:To investigate the effects of 3-dimensional conformal radiation therapy(3 DCRT) on the pancreatic cancer and the quality of life(QOL) of patients,and anal yze the factors that influence the prognosis of pancreatic cancer. METHODS:Total ly 31 patients with pancreatic cancer were treated with 3DCRT only.The local con trol rates of the cancer and the overall 1-year and 2-year survival rates were noted,thirteen items,including daily life and activity,pain,appetite,sleep,etc. were synthetically assessed by using quality of life scale,and the factors that might influence the prognosis were analyzed with the Cox proportional hazard mod el in multivariate analysis. RESULTS:The local control rates were 58.1% and 32.3% at 3 and 12 months re spectively.The overall 1-year and 2-year accumulative survival rates were 38.2 % and 7.6% respectively,with the median survival time of 8.3 months.The mult iple factor analysis showed that clinical staging and scores of quality of life had statistical significance for the survival rate of the patients(P< 0.05).CONCLUSION:In the treatment of pancreatic cancer with 3DCRT,the QOL and the su rvival rate of the patients can obviously be improved.Clinical staging and QOL a re the two major factors for prognosis.
出处 《中国临床康复》 CSCD 2004年第11期2010-2011,共2页 Chinese Journal of Clinical Rehabilitation
  • 相关文献

参考文献14

  • 1Azria D, Ychou M, Jacot W, et al. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas 2002; 25 (4): 360 - 5
  • 2Mawdsley S, Hall M, Glynne-Jones R. Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil. Clin Oncol (R Coll Radiol) 2002; 14(4): 308- 12
  • 3Shinchi H, Takao S, Noma H, et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J RadiatOncol Biol Phys 2002; 53(1): 146 -50
  • 4Carroll DL, Hamilton GA, Kenney BJ. Changes in health status, psychological distress, and quality of life in implantable cardioverter defibrillator recipients between 6 months and 1 year after implantation. Eur J Cardiovasc Nurs 2002;1(3):213-9
  • 5Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003;57(1 ): 98 - 104
  • 6Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002; 52(5): 1293 - 302
  • 7Woudstra E, Heijmen BJ. Automated beam angle and weight selection in radiotherapy treatment planning applied to pancreas tumors. Int J Radiat Oncol Biol Phys 2003; 56(3): 878 - 88
  • 8Ito Y, Okusaka T, Kagami Y, et al. Evaluation of acute intestinal toxicity in relation to the volume of irradiated small bowel in patients treated with concurrent weekly gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Radiat Onc
  • 9吴健雄,邵永孚,荣维淇,单毅,高纪东,吴铁成.178例胰头癌的诊治分析[J].中华肿瘤杂志,2002,24(5):497-500. 被引量:20
  • 10王奇璐.胰腺癌[A]//孙燕内科肿瘤学[M].北京:人民卫生出版社,2001.630-9.

二级参考文献19

  • 1钟守先.积极开展胰头癌根治术——为提高五年生存率而努力[J].中华肝胆外科杂志,1998,4(5):267-268. 被引量:14
  • 2刘嘉湘,廖美琳,严德钧,周吉燕.康莱特注射液治疗原发性肺癌Ⅱ期临床总结[J].中药新药与临床药理,1995,6(4):17-22. 被引量:40
  • 3Birgir Gudjonsson. Carcinoma of the pancreas: critical analysis of costs, results of resections, and the need for standardized reporting. Am Coll Surg, 1995, 181:483-503.
  • 4Adsay NV, Conlon KC, Zee SY, et al. Intraductal papillary-mucinous neoplasms of the pancreas: an analysis of in situ and invasive carcinomas in 28 patients. Cancer, 2002, 94:62-77.
  • 5Bluemke DA, Cameron JL, Hruban RH. Potentially respectable pancreatic adenocarcinoma: spiral CT assessment with surgical and pathologic correlation. Radiology, 1995, 197:381-385.
  • 6Banfi G, Zerbi A, Pastori S, et al. Behavior of tumor markers. CA19-9, CA195, CAM43, CA242, and TPS in the diagnosis and follow-up of pancreatic cancer. Clin Chem, 1993, 39: 420-423.
  • 7Tian F, Appert HE, Myles J, et al. Prognostic value of serum CA19-9 levels in pancreatic adenocarcinoma. Ann Surg, 1992, 215: 350-355.
  • 8Paulino AC, Latona C. Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results. Cancer Invest, 2000, 18: 309-313.
  • 9Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas- 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg, 2000, 4: 567-579.
  • 10钱明山,刘之江.康莱特抗肿瘤的研究[M].杭州:浙江大学出版社,1998:214-229.

共引文献57

同被引文献69

引证文献4

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部